William Blair & Company
SPRY icon

William Blair & Company’s ARS Pharmaceuticals SPRY Stock Holding History

William Blair & Company’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$86.9K Sell
10,825
-775
-7% -$7.43K ﹤0.01% 1615
2025
Q4 		$135K Buy
+11,600
New +$113K ﹤0.01% 1526

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

William Blair & Company's SPRY Position: Q1 2026 in Review

William Blair & Company reduced its ARS Pharmaceuticals (SPRY) stake by 6.7% in Q1 2026, selling an estimated $7.43K and leaving 10,825 shares worth $86.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1615.

William Blair & Company first reported a position in SPRY in Q4 2025 and has held it in 2 quarters since. The position peaked at $135K in Q4 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • William Blair & Company held 10,825 shares of ARS Pharmaceuticals worth $86.9K as of Q1 2026.
  • William Blair & Company sold 775 ARS Pharmaceuticals shares in Q1 2026, an estimated $7.43K.
  • ARS Pharmaceuticals made up ﹤0.01% of William Blair & Company's portfolio in Q1 2026, its #1615 holding.
  • William Blair & Company first reported a position in ARS Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • William Blair & Company's ARS Pharmaceuticals position peaked at $135K in Q4 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.